KALITA, Ondrej, Tomáš KAZDA, Stefan REGULI, Radim JANČÁLEK, Pavel FADRUS, Marek SLACHTA, Petr POSPÍŠIL, Lukas KRSKA, Jana VRBKOVA, Lumir HRABALEK, Martin SMRČKA a Radim LIPINA. Effects of Reoperation Timing on Survival among Recurrent Glioblastoma Patients: A Retrospective Multicentric Descriptive Study. Cancers. BASEL: MDPI, 2023, roč. 15, č. 9, s. 1-17. ISSN 2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers15092530.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Effects of Reoperation Timing on Survival among Recurrent Glioblastoma Patients: A Retrospective Multicentric Descriptive Study
Autoři KALITA, Ondrej (203 Česká republika), Tomáš KAZDA (203 Česká republika, garant, domácí), Stefan REGULI (203 Česká republika), Radim JANČÁLEK (203 Česká republika, domácí), Pavel FADRUS (203 Česká republika, domácí), Marek SLACHTA (203 Česká republika), Petr POSPÍŠIL (203 Česká republika, domácí), Lukas KRSKA (203 Česká republika), Jana VRBKOVA (203 Česká republika), Lumir HRABALEK (203 Česká republika), Martin SMRČKA (203 Česká republika, domácí) a Radim LIPINA (203 Česká republika).
Vydání Cancers, BASEL, MDPI, 2023, 2072-6694.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.200 v roce 2022
Kód RIV RIV/00216224:14110/23:00131197
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3390/cancers15092530
UT WoS 000987086900001
Klíčová slova anglicky glioblastoma; reoperation timing; treatment strategy
Štítky 14110131, 14110224, 14110812, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 14. 2. 2024 09:11.
Anotace
Glioblastoma inevitably recurs, but no standard regimen has been established for treating this recurrent disease. Several reports claim that reoperative surgery can improve survival, but the effects of reoperation timing on survival have rarely been investigated. We, therefore, evaluated the relationship between reoperation timing and survival in recurrent GBM. A consecutive cohort of unselected patients (real-world data) from three neuro-oncology cancer centers was analyzed (a total of 109 patients). All patients underwent initial maximal safe resection followed by treatment according to the Stupp protocol. Those meeting the following criteria during progression were indicated for reoperation and were further analyzed in this study: (1) The tumor volume increased by >20-30% or a tumor was rediscovered after radiological disappearance; (2) The patient's clinical status was satisfactory (KS = 70% and PS WHO = gr. 2); (3) The tumor was localized without multifocality; (4) The minimum expected tumor volume reduction was above 80%. A univariate Cox regression analysis of postsurgical survival (PSS) revealed a statistically significant effect of reoperation on PSS from a threshold of 16 months after the first surgery. Cox regression models that stratified the Karnofsky score with age adjustment confirmed a statistically significant improvement in PSS for time-to-progression (TTP) thresholds of 22 and 24 months. The patient groups exhibiting the first recurrence at 22 and 24 months had better survival rates than those exhibiting earlier recurrences. For the 22-month group, the HR was 0.5 with a 95% CI of (0.27, 0.96) and a p-value of 0.036. For the 24-month group, the HR was 0.5 with a 95% CI of (0.25, 0.96) and a p-value of 0.039. Patients with the longest survival were also the best candidates for repeated surgery. Later recurrence of glioblastoma was associated with higher survival rates after reoperation.
Návaznosti
MUNI/A/1379/2022, interní kód MUNázev: Organotypické kultury glioblastomu – personalizované testování protinádorové léčby II
Investor: Masarykova univerzita, Organotypické kultury glioblastomu – personalizované testování protinádorové léčby II
VytisknoutZobrazeno: 21. 7. 2024 00:23